



CERTIFICATION OF ANALYSIS	
Product: Tirzepatide 36mg/2mL (18 mg/mL vial)	NDC: 84139-218-02
Test Date: 24 Sep 2025	Batch No.: ProRx09182025@3
Date of Mfg: 18 Sep 2025	Date of Exp: 18 Sep 2026

Test	Specification	Result
Appearance	Clear solution	Conforms
Tirzepatide content	16.2 to 19.8 mg/mL	17.8 mg/mL
Phenol content	4.5 to 5.5 mg/mL	5.0 mg/mL
Sterility by ScanRDI	Conforms to sterility test as per USP <71>	Pass
Endotoxin	Conforms to specifications as per USP <85>	Pass
Particulate	Conforms to specifications as per USP <788>	Pass

Results excluding appearance transcribed from third-party testing from Prompt Praxis Laboratories.

Conclusion: Test results comply with product specifications

Approved by: Initials/Date	<i>Matthew Bross</i>	2025-10-01
Reviewed by: Initials/Date	<i>Jessica Borie</i>	2025-10-01

Audit trail

Details

FILE NAME COA-Tirzepatide 36mg2mL ProRx09182025@3

STATUS ● Signed

STATUS TIMESTAMP 2025/10/01
14:44:13 UTC

Activity



cynthia@prorxpharma.com **sent** a signature request to:

- Matthew Bross (matthew@prorxpharma.com)
- Jessica Borie (jessica@prorxpharma.com)

2025/10/01
12:36:51 UTC



Signed by Jessica Borie (jessica@prorxpharma.com)

2025/10/01
12:47:08 UTC



Signed by Matthew Bross (matthew@prorxpharma.com)

2025/10/01
14:44:13 UTC



This document has been signed by all signers and is **complete**

2025/10/01
14:44:13 UTC

The email address indicated above for each signer may be associated with a Google account, and may either be the primary email address or secondary email address associated with that account.